PMID- 26308162
OWN - NLM
STAT- MEDLINE
DCOM- 20160822
LR  - 20220414
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 6
IP  - 29
DP  - 2015 Sep 29
TI  - A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): 
      Old successes and future perspectives.
PG  - 26814-25
LID - 10.18632/oncotarget.4254 [doi]
AB  - The discovery of Epidermal Growth Factor Receptor (EGFR) mutations in Non Small 
      Cell Lung Cancer (NSCLC) launched the era of personalized medicine in advanced 
      NSCLC, leading to a dramatic shift in the therapeutic landscape of this disease. 
      After ten years from the individuation of activating mutations in the tyrosine 
      kinase domain of the EGFR in NSCLC patients responding to the EGFR tyrosine 
      kinase inhibitor (TKI) Gefitinib, several progresses have been done and first 
      line treatment with EGFR TKIs is a firmly established option in advanced 
      EGFR-mutated NSCLC patients. During the last decade, different EGFR TKIs have 
      been developed and three inhibitors have been approved so far in these selected 
      patients. However, despite great breakthroughs have been made, treatment of these 
      molecularly selected patients poses novel therapeutic challenges, such as 
      emerging of acquired resistance, brain metastases development or the need to 
      translate these treatments in earlier clinical settings, such as adjuvant 
      therapy. The aim of this paper is to provide a comprehensive review of the major 
      progresses reported so far in the EGFR inhibition in this molecularly-selected 
      subgroup of NSCLC patients, from the early successes with first generation EGFR 
      TKIs, Erlotinib and Gefitinib, to the novel irreversible and mutant-selective 
      inhibitors and ultimately the emerging challenges that we, in the next future, 
      are called to deal with.
FAU - Russo, Alessandro
AU  - Russo A
AD  - Medical Oncology Unit AOOR Papardo-Piemonte & Department of Human Pathology, 
      University of Messina, Messina, Italy.
FAU - Franchina, Tindara
AU  - Franchina T
AD  - Medical Oncology Unit AOOR Papardo-Piemonte & Department of Human Pathology, 
      University of Messina, Messina, Italy.
FAU - Ricciardi, Giuseppina Rosaria Rita
AU  - Ricciardi GR
AD  - Medical Oncology Unit AOOR Papardo-Piemonte & Department of Human Pathology, 
      University of Messina, Messina, Italy.
FAU - Picone, Antonio
AU  - Picone A
AD  - Medical Oncology Unit AOOR Papardo-Piemonte & Department of Human Pathology, 
      University of Messina, Messina, Italy.
FAU - Ferraro, Giuseppa
AU  - Ferraro G
AD  - Medical Oncology Unit AOOR Papardo-Piemonte & Department of Human Pathology, 
      University of Messina, Messina, Italy.
FAU - Zanghi, Mariangela
AU  - Zanghi M
AD  - Medical Oncology Unit AOOR Papardo-Piemonte & Department of Human Pathology, 
      University of Messina, Messina, Italy.
FAU - Toscano, Giuseppe
AU  - Toscano G
AD  - Medical Oncology Unit AOOR Papardo-Piemonte & Department of Human Pathology, 
      University of Messina, Messina, Italy.
FAU - Giordano, Antonio
AU  - Giordano A
AD  - Sbarro Institute for Cancer Research and Molecular Medicine, Center for 
      Biotechnology, Temple University, Philadelphia, Pennsylvania, USA.
FAU - Adamo, Vincenzo
AU  - Adamo V
AD  - Medical Oncology Unit AOOR Papardo-Piemonte & Department of Human Pathology, 
      University of Messina, Messina, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Quinazolines)
RN  - DA87705X9K (Erlotinib Hydrochloride)
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - EC 2.7.10.1 (Protein-Tyrosine Kinases)
RN  - S65743JHBS (Gefitinib)
SB  - IM
MH  - Antineoplastic Agents/therapeutic use
MH  - Brain Neoplasms/pathology/secondary
MH  - Carcinoma, Non-Small-Cell Lung/drug therapy/*metabolism
MH  - Clinical Trials as Topic
MH  - Drug Resistance, Neoplasm
MH  - ErbB Receptors/*antagonists & inhibitors/*genetics
MH  - Erlotinib Hydrochloride/therapeutic use
MH  - Gefitinib
MH  - Humans
MH  - Lung Neoplasms/drug therapy/*metabolism
MH  - Medical Oncology/trends
MH  - *Mutation
MH  - Neoplasm Metastasis
MH  - Protein Kinase Inhibitors/therapeutic use
MH  - Protein-Tyrosine Kinases/antagonists & inhibitors
MH  - Quinazolines/therapeutic use
PMC - PMC4694955
OTO - NOTNLM
OT  - EGFR mutations
OT  - non small cell lung cancer
OT  - targeted therapy
OT  - third generation EGFR TKIs
OT  - tyrosine kinase inhibitors
COIS- CONFLICTS OF INTEREST None.
EDAT- 2015/08/27 06:00
MHDA- 2016/08/23 06:00
PMCR- 2015/09/29
CRDT- 2015/08/27 06:00
PHST- 2015/04/25 00:00 [received]
PHST- 2015/06/01 00:00 [accepted]
PHST- 2015/08/27 06:00 [entrez]
PHST- 2015/08/27 06:00 [pubmed]
PHST- 2016/08/23 06:00 [medline]
PHST- 2015/09/29 00:00 [pmc-release]
AID - 4254 [pii]
AID - 10.18632/oncotarget.4254 [doi]
PST - ppublish
SO  - Oncotarget. 2015 Sep 29;6(29):26814-25. doi: 10.18632/oncotarget.4254.